Our analysis categorized the tumors into 6 immune subtypes, including C1 (wound healing), C2 (IFN-gamma dominant), C3 (inflammatory), C4 (lymphocyte depleted), C5 (immunologically quiet), and C6 (TGF-b dominant), based on their immune activity and observed significant associations between TUBA1B expression and immune subtypes in 18 different cancers, including BLCA, BRCA, COAD, ESCA, HNSC, KIRP, LGG, LIHC, LUAD, LUSC, OV, PAAD, PCPG, PRAD, SARC, STAD, THCA, and UCEC. Here, TUBA1B is linked to cancer.